Asset profile
GSK5764227
Small molecule
Evidence outlook · registrational
Non-Small Cell Lung Cancer: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2028-12-31.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
66 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 58 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| GSK5764227: this drug | Phase 3 | Small molecule | B7-H3 | ||
| 7MW3711 | Phase 3 | Antibody–drug conjugate | B7-H3 | ||
| BNT324 | Phase 3 | Antibody–drug conjugate | B7-H3 | ||
| Ifinatamab Deruxtecan | Phase 3 | Antibody–drug conjugate | B7-H3 | ||
| YL201 | Phase 3 | Small molecule | B7-H3 | ||
| 177Lu-BetaBart | Phase 1/2 | Radiopharmaceutical | B7-H3 | ||
| ITC-6146RO | Phase 1 | Antibody–drug conjugate | B7-H3 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A |
…and 51 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (3)
July 2027 (1)
What to watch
August 2027 (1)
What to watch
November 2027 (1)
What to watch
2028 (3)
January 2028 (1)
What to watch
February 2028 (1)
December 2028 (1)
What to watch
2030 (1)
June 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.